Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive ...

Unlike the Illumina and Life Technologies sequencing ... has been about the development of so-called third-generation DNA sequencing platforms. Designed to complement second-generation sequencing ...

Illumina is a global leader in developing the tools that help scientists analyze strands of DNA as well as large amounts of ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

Roche, Illumina and Life Technologies ... Figure 2: Enrichment of A-B–tagged DNA fragments. We performed deep sequencing of the Nextera-enriched dual-tagged library and of a control library ...

In early March, China banned imports of Illumina’s DNA sequencing instruments after the White House doubled the 10% tariff it had levied on the country the month before. Shortly after ...

The genetic sequencing market could grow to $75 billion by 2033. Illumina ranks as the largest player in genetic sequencing. Other top genetic sequencing companies include PacBio, 10X Genomics ...